# Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

> **NCT05103423** · PHASE1,PHASE2 · COMPLETED · sponsor: **Staidson (Beijing) Biopharmaceuticals Co., Ltd** · enrollment: 50 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** BDB-001 Injection
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05103423
- **Lead sponsor:** Staidson (Beijing) Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-24
- **Primary completion:** 2023-07-07
- **Final completion:** 2023-07-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2024-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05103423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05103423, "Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05103423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*